It is used for the treatment of wet macular degeneration and is administered as an intravitreal injection, that is, into the eye. For cancer treatment, is given intravenously in combination with the other cancer drugs 5-fluorouracil and irinotecan and the adjuvant folinic acid. On 27 August 2014, Eylea was also indicated for the treatment of people with visual impairment due to diabetic macular oedema, according to the updated summary of product characteristics. In May 2019 FDA expanded the indication for<unk>  to include all stages of diabetic retinopathy.
Aflibercept
Vatalanib
Nintedanib
Ranibizumab
Angiozyme
Avelumab
Gilteritinib
Abrocitinib